Maternal and Perinatal Pregnancy Outcome in Women With Heterozygous Hemoglobinopathies

NCT ID: NCT03837119

Last Updated: 2024-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

540 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-04

Study Completion Date

2021-04-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This retrospective study aims to investigate pregnancy outcome in women with heterozygous hemoglobinopathies (regarding gestational diabetes, cholestasis and urinary tract infections) and to analyze if there are aggravated maternal and/or perinatal risks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heterozygous Haemoglobinopathy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pregnancy gestational diabetes cholestasis in pregnancy urinary tract infection in pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Heterozygous Hemoglobinopathy

pregnancy outcome in women with heterozygous hemoglobinopathy

pregnancy outcome

Intervention Type OTHER

descriptive statistics of variables

No Heterozygous Hemoglobinopathy

pregnancy outcome in women without heterozygous hemoglobinopathy

pregnancy outcome

Intervention Type OTHER

descriptive statistics of variables

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pregnancy outcome

descriptive statistics of variables

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pregnant women with or without heterozygous hemoglobinopathy

Exclusion Criteria

* refusal of study participation
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Irene Hoesli, Prof. Dr. MD

Role: PRINCIPAL_INVESTIGATOR

Frauenklinik Universitätsspital Basel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Frauenklinik University Hospital Basel

Basel, , Switzerland

Site Status

Frauenklinik University Hospital Zürich

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Kasparek J, Burkhardt T, Hoesli I, Amstad Bencaiova G. Pregnancy outcomes in women with a hemoglobinopathy trait: a multicenter, retrospective study. Arch Gynecol Obstet. 2021 Nov;304(5):1197-1203. doi: 10.1007/s00404-021-06058-y. Epub 2021 Apr 11.

Reference Type RESULT
PMID: 33842991 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-00101; sp19Hoesli

Identifier Type: -

Identifier Source: org_study_id